Osaterone acetate

Overview

Osaterone acetate, sold under the brand name Ypozane, is a medication which is used in veterinary medicine for the treatment of enlarged prostate in dogs. It is given by mouth.[1][2][3] WP

Osaterone acetate is an antiandrogen, and hence is an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. It is also a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[1] WP

Osaterone acetate was introduced for veterinary use in 2007.[1][4][5][6] WP

Uses, dosage and effects

Veterinary

Osaterone acetate is used in veterinary medicine for the treatment of benign prostatic hyperplasia (BPH) in dogs. It has been found to produce remission of clinical symptoms of BPH in 83% of dogs for six months after a single one-week course of treatment, and can be used long-term.[1][2][3][7] WP

Available forms

Osaterone acetate comes in the form of 1.875 mg, 3.75 mg, 7.5 mg, and 15 mg oral tablets for veterinary use.[1] WP

Risks and side effects

Side effects

Side effects of osaterone acetate include diminished sperm quality (for up to 6 weeks post-treatment), transient elevation of liver enzymes (caution should be observed with known liver disease), vomiting, diarrhea, polyuria/polydipsia, lethargy, and hyperplasia of the mammary glands. It can also decrease cortisol levels, interfere with adrenocorticotropic hormone response, induce or exacerbate adrenal insufficiency, and exacerbate diabetes mellitus.[8][9] WP

Pharmacology

Pharmacodynamics

Osaterone acetate is a steroidal antiandrogen, progestin, and antigonadotropin. It has virtually no estrogenic or androgenic activity. Its side-effect profile indicates that it possesses clinically relevant glucocorticoid activity. An active metabolite of osaterone acetate, 15β-hydroxyosaterone acetate, has potent antiandrogenic activity similarly to osaterone acetate. Osaterone acetate treats BPH in dogs by reducing the actions of androgens in the prostate gland.[1][2][8][9] WP

Pharmacokinetics

The major active metabolite of osaterone acetate is 15β-hydroxyosaterone acetate. Osaterone acetate has a long biological half-life of 80 hours to 197 ± 109 hours in dogs.[1][10] WP

Research

Research

Osaterone acetate was also investigated in Japan in the treatment of prostate cancer and BPH in humans but was ultimately never marketed for such purposes.[2][11] WP

History

History

Osaterone acetate was approved for veterinary use in the European Union under the brand name Ypozane in 2007.[1][4][5][6] WP

Legal status

Generic names

Osaterone acetate is the generic name of the drug. Osaterone is the INN (International Nonproprietary Name) of the deacetylated parent compound.[4][6] WP

Brand names

Osaterone acetate is marketed under the brand name Ypozane by Virbac throughout the European Union.[4][6] WP

Chemistry

Formula

C22H27ClO5 PC

CAS number

105149-00-6 PC

Molar mass (g/mol)

406.9 PC

IUPAC name (computed by PubChem)

[(1R,3aS,3bR,9aR,9bS,11aS)-1-acetyl-5-chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,9,9b,10,11-octahydroindeno[4,5-h]isochromen-1-yl] acetate PC

SMILES

CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)OC[C@]34C)Cl)C)OC(=O)C PC

InChIKey

KKTIOMQDFOYCEN-OFUYBIASSA-N PC

PubChem CID

114992

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Ypozane for Dogs
2. Other Weber GF. Molecular Therapies of Cancer. 22 July 2015
3. Other Greer ML. Canine Reproduction and Neonatology. 18 December 2014
4. Journal / agency Ypozane EPAR. 18 January 2007
5. Journal / agency Emmerich IU, Ungemach FR. Neue Arzneimittel für Kleintiere 2007. Tierärztliche Praxis Ausgabe K: Kleintiere/Heimtiere. 2008. doi:10.1055/s-0038-1622691
6. Other Osaterone
7. Other Cote E. Clinical Veterinary Advisor: Dogs and Cats. 9 December 2014
8. Other Lamm C, Makloski C. Theriogenology, An Issue of Veterinary Clinics: Small Animal Practice. 28 May 2012
9. Other Ettinger SJ, Feldman EC. Textbook of Veterinary Internal Medicine. 24 December 2009
10. Other Maddison JE, Page SW, Church D. Small Animal Clinical Pharmacology. 2008
11. Journal / agency Schröder FH, Radlmaier A. Hormone Therapy in Breast and Prostate Cancer. 2009. doi:10.1007/978-1-59259-152-7_15

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.